Table of Contents

Research Articles

• Research Articles

  Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing

  Arianne M. Brandsma, Toine ten Broeke, Maaike Nederend, Laura A.P.M. Meulenbroek, Geert van Tetering, Saskia Meyer, J.H. Marco Jansen, M. Alejandra Beltrán Buitrago, Sietse Q. Nagelkerke, István Németh, Ruud Ubink, Gerard Rouwendal, Stefan Lohse, Thomas Valerius, Jeanette H.W. Leusen and Peter Boross

  Cancer Immunol Res December 1 2015 3 (12) 1316-1324; DOI:10.1158/2326-6066.CIR-15-0099-T

  
  

  The efficacy of anticancer monoclonal antibodies (mAbs) is limited by the exhaustion of cellular effector mechanisms. The combination of IgG and IgA to two different tumor targets leads to enhanced cytotoxicity, providing a basis for therapeutic mAb improvements.

• Research Articles

  Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy

  Michael J. Campa, Elizabeth B. Gottlin, Ryan T. Bushey and Edward F. Patz Jr

  Cancer Immunol Res December 1 2015 3 (12) 1325-1332; DOI:10.1158/2326-6066.CIR-15-0122

  
  

  Select early-stage lung cancer patients never develop metastasis. Some of these patients have antibodies that inactivate a protein that protects tumor cells from complement lysis, thus making tumor cells more susceptible to being killed.

• Research Articles

  Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors

  Claudia Voena, Matteo Menotti, Cristina Mastini, Filomena Di Giacomo, Dario Livio Longo, Barbara Castella, Maria Elena Boggio Merlo, Chiara Ambrogio, Qi Wang, Valerio Giacomo Minero, Teresa Poggio, Cinzia Martinengo, Lucia D'Amico, Elena Panizza, Luca Mologni, Federica Cavallo, Fiorella Altruda, Mohit Butaney, Marzia Capelletti, Giorgio Inghirami, Pasi A. Jänne and Roberto Chiarle

  Cancer Immunol Res December 1 2015 3 (12) 1333-1343; DOI:10.1158/2326-6066.CIR-15-0089

  
  

  Lung cancers harboring ALK translocations are treated with protein kinase inhibitors, which can extend survival. A cancer vaccine against ALK induced strong immune responses and enhanced survival when used alone, or in combination with kinase inhibitors or checkpoint inhibitors.

• Research Articles | AuthorChoice

  Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

  Daniela S. Thommen, Jens Schreiner, Philipp Müller, Petra Herzig, Andreas Roller, Anton Belousov, Pablo Umana, Pavel Pisa, Christian Klein, Marina Bacac, Ozana S. Fischer, Wolfgang Moersig, Spasenija Savic Prince, Victor Levitsky, Vaios Karanikas, Didier Lardinois and Alfred Zippelius

  Cancer Immunol Res December 1 2015 3 (12) 1344-1355; DOI:10.1158/2326-6066.CIR-15-0097

  
  

  T cells within non–small cell lung cancer tumors acquire greater numbers, and more diversity, of inhibitory receptors as tumors progress, correlating with a loss in function as well as in their ability to be reactivated after anti-checkpoint treatment.

• Research Articles

  Prognostic Significance of CD169⁺ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma

  Yoichi Saito, Koji Ohnishi, Azusa Miyashita, Satoshi Nakahara, Yukio Fujiwara, Hasita Horlad, Takanobu Motoshima, Satoshi Fukushima, Masatoshi Jinnin, Hironobu Ihn, Motohiro Takeya and Yoshihiro Komohara

  Cancer Immunol Res December 1 2015 3 (12) 1356-1363; DOI:10.1158/2326-6066.CIR-14-0180

  
  

  Prognostic indicators are needed for malignant melanoma. The presence of high densities of CD169⁺ macrophages in the draining lymph nodes of patients significantly correlates with CTL infiltration and longer overall survival, providing a potentially useful biomarker.

• Research Articles

  Effector CD8⁺ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent

  C. Bryce Johnson, Brian P. Riesenberg, Bennett R. May, Stuart C. Gilreath, Guangfu Li, Kevin F. Staveley-O'Carroll, Elizabeth Garrett-Mayer, Shikhar Mehrotra, David J. Cole and Mark P. Rubinstein

  Cancer Immunol Res December 1 2015 3 (12) 1364-1374; DOI:10.1158/2326-6066.CIR-15-0087-T

  
  

  Adoptive cellular immunotherapy requires donor cells to survive and accumulate, which this study shows requires an IL12/IL7 axis in activated CD8⁺ T cells. IL12 leads to enhanced IL7Ra expression and IL7 responsiveness, which maximizes antitumor efficacy.

• Research Articles

  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

  David M. Woods, Andressa L. Sodré, Alejandro Villagra, Amod Sarnaik, Eduardo M. Sotomayor and Jeffrey Weber

  Cancer Immunol Res December 1 2015 3 (12) 1375-1385; DOI:10.1158/2326-6066.CIR-15-0077-T

  
  

  Combining other agents with immune-based approaches can enhance treatment for melanoma. PDL-1 gene expression was increased after inhibition of histone deacetylases. Combining PD-1–blockade immunotherapy with histone deacetylase inhibition increased responses in a mouse model of melanoma.